financetom
FMS
financetom
/
Healthcare
/
FMS
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Fresenius Medical Care AG & Co. KGaAFMS
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.

The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.

In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services.

The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents.

Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Latest News >
--Pure Storage Guides For Q2 Revenue of $755 Million, vs CIQ Analyst Consensus of $752 Million; FY 2025 Revenue Seen at $3.1 Billion, vs Consensus of $3.1 Billion
--Pure Storage Guides For Q2 Revenue of $755 Million, vs CIQ Analyst Consensus of $752 Million; FY 2025 Revenue Seen at $3.1 Billion, vs Consensus of $3.1 Billion
May 29, 2024
04:11 PM EDT, 05/29/2024 (MT Newswires) -- Price: 62.20, Change: -0.81, Percent Change: -1.28 ...
Salesforce forecasts second-quarter revenue below estimates
Salesforce forecasts second-quarter revenue below estimates
May 29, 2024
(Reuters) - Salesforce ( CRM ) forecast second-quarter revenue below Wall Street expectations on Wednesday, on weak client spending on its cloud and enterprise business products in an uncertain economy, sending its shares down 9% in extended trading. The company forecast revenue between $9.20 billion and $9.25 billion compared with estimates of $9.37 billion, according to LSEG data. Salesforce's (...
--C3.ai Guides For Q1 Revenue of $84-$89 Million, vs CIQ Analyst Consensus of $86 Million; FY 2025 Revenue Seen at $370-$395 Million, vs Consensus of $368 Million
--C3.ai Guides For Q1 Revenue of $84-$89 Million, vs CIQ Analyst Consensus of $86 Million; FY 2025 Revenue Seen at $370-$395 Million, vs Consensus of $368 Million
May 29, 2024
04:09 PM EDT, 05/29/2024 (MT Newswires) -- Price: 27.10, Change: +3.18, Percent Change: +13.29 ...
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
Insulet Insider Sold Shares Worth $596,970, According to a Recent SEC Filing
May 29, 2024
04:11 PM EDT, 05/29/2024 (MT Newswires) -- Timothy J Scannell, Director, on May 28, 2024, sold 3,300 shares in Insulet ( PODD ) for $596,970. Following the Form 4 filing with the SEC, Scannell has control over a total of 42,586 shares of the company, with 42,586 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1145197/000112760224016771/xslF345X03/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved